Emerging role of multikinase inhibitors for refractory thyroid cancer

References

• SiegelRWardEBrawleyOJemalACancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin201161421223621685461
   PubMed Web of Science ®Google Scholar
• Eustatia-RuttenCFCorssmitEPBiermaszNRPereiraAMRomijnJASmitJWSurvival and death causes in differentiated thyroid carcinomaJ Clin Endocrinol Metab200691131331916263822
   PubMed Web of Science ®Google Scholar
• GottliebJAHillCSJrChemotherapy of thyroid cancer with adriamycin. Experience with 30 patientsN Engl J Med197429041931974808917
   PubMed Web of Science ®Google Scholar
• ShimaokaKSchoenfeldDDeWysWDCreechRHDeContiRA randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinomaCancer1985569215521603902203
   PubMed Web of Science ®Google Scholar
• NikiforovYEOhoriNPHodakSPImpact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samplesJ Clin Endocrinol Metab201196113390339721880806
   PubMed Web of Science ®Google Scholar
• CommanderHWhitesideGPerryCVandetanib: first global approvalDrugs201171101355136521770481
   PubMed Web of Science ®Google Scholar
• RobertsPJDerCJTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancerOncogene200726223291331017496923
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation in thyroid cancerEndocr Relat Cancer200512224526215947100
   PubMed Web of Science ®Google Scholar
• HendersonYCShellenbergerTDWilliamsMDHigh rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinomaClin Cancer Res200915248549119147753
   PubMed Web of Science ®Google Scholar
• LupiCGianniniRUgoliniCAssociation of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinomaJ Clin Endocrinol Metab200792114085409017785355
   PubMed Web of Science ®Google Scholar
• XingMWestraWHTufanoRPBRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancerJ Clin Endocrinol Metab200590126373637916174717
   PubMed Web of Science ®Google Scholar
• WeisSMChereshDATumor angiogenesis: molecular pathways and therapeutic targetsNat Med201117111359137022064426
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• BunoneGVigneriPMarianiLExpression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological featuresAm J Pathol199915561967197610595926
   PubMed Web of Science ®Google Scholar
• KleinMPicardEVignaudJMVascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinomaJ Endocrinol19991611414910194527
   PubMed Web of Science ®Google Scholar
• LennardCMPatelAWilsonJIntensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancerSurgery2001129555255811331447
   PubMed Web of Science ®Google Scholar
• MologniLDevelopment of RET kinase inhibitors for targeted cancer therapyCurr Med Chem201118216217521110809
   PubMed Web of Science ®Google Scholar
• HouvrasYCompleting the arc: targeted inhibition of RET in medullary thyroid cancerJ Clin Oncol201230220020222162569
   PubMed Web of Science ®Google Scholar
• LangmuirPBYverAClin Pharmacol Ther20121911718022158569
   PubMed Web of Science ®Google Scholar
• WellsSAJrGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• RobinsonBGPaz-AresLKrebsAVasselliJHaddadRVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Endocrinol Metab20109562664267120371662
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol201230213414122025146
   PubMed Web of Science ®Google Scholar
• GramzaAWWellsSABalasubramaniamSFojoATPhase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: phase I results [abstract]J Clin Oncol201129Suppl5565
   Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• BibleKCSumanVJMolinaJREfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyLancet Oncol2010111096297220851682
   PubMed Web of Science ®Google Scholar
• ShermanSIJarzabBCabanillasMEA phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)- refractory differentiated thyroid cancer (DTC) [abstract]J Clin Oncol201129Suppl5503
   Web of Science ®Google Scholar
• ShumakerRZhouMRenMFanJMartinezGDarpoBLenvatinib (E7080) does not prolong the QTc interval: results from a thorough QT study in healthy volunteers [abstract]Mol Cancer Ther20111011 Suppl 1C116
   Google Scholar
• KloosRTRingelMDKnoppMVPhase II trial of sorafenib in metastatic thyroid cancerJ Clin Oncol200927101675168419255327
   PubMed Web of Science ®Google Scholar
• Gupta-AbramsonVTroxelABNelloreAPhase II trial of sorafenib in advanced thyroid cancerJ Clin Oncol200826294714471918541894
   PubMed Web of Science ®Google Scholar
• BroseMSTroxelABRedlingerMEffect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients [abstract]J Clin Oncol200927Suppl 156002
   Web of Science ®Google Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol201028142323233020368568
   PubMed Web of Science ®Google Scholar
• RosenLSKurzrockRMulayMSafety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumorsJ Clin Oncol200725172369237617557949
   PubMed Web of Science ®Google Scholar
• ShermanSIWirthLJDrozJPMotesanib diphosphate in progressive differentiated thyroid cancerN Engl J Med20083591314218596272
   PubMed Web of Science ®Google Scholar
• SchlumbergerMJEliseiRBastholtLPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerJ Clin Oncol200927233794380119564535
   PubMed Web of Science ®Google Scholar
• BassMBShermanSISchlumbergerMJBiomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancerJ Clin Endocrinol Metab201095115018502720739388
   PubMed Web of Science ®Google Scholar
• CohenEENeedlesBMCullenKJPhase 2 study of sunitinib in refractory thyroid cancer [abstract]J Clin Oncol200826Suppl6025
   Web of Science ®Google Scholar
• GoulartBCarrLMartinsRGPhase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) [abstract]J Clin Oncol200826Suppl6062
   Google Scholar
• RavaudAde la FouchardiereCCourbonFSunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial [abstract]J Clin Oncol200826Suppl6058
   Web of Science ®Google Scholar
• InaiTMancusoMHashizumeHInhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghostsAm J Pathol20041651355215215160
   PubMed Web of Science ®Google Scholar
• MancusoMRDaviasRNorbergSMRapid vascular regrowth in tumors after reversal of VEGF inhibitionJ Clin Invest2006116102610262117016557
   PubMed Web of Science ®Google Scholar
• KambaTTamBYHashizumeHVEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculatureAm J Physiol Heart Circ Physiol20062902H560H57616172168
   PubMed Web of Science ®Google Scholar
• BaffertFLeTSenninoBCellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signalingAm J Physiol Heart Circ Physiol20062902H547H55916172161
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetics and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• CohenEERosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyJ Clin Oncol200826294708471318541897
   PubMed Web of Science ®Google Scholar
• JolyAHSimultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effectsEur J Cancer2006Suppl 43517098420
   PubMed Web of Science ®Google Scholar
• SenninoBNaylorRMTabruynSPYouWKAftabDTMcDonaldDMReduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 [abstract]Mol Cancer Ther2011812 Suppl 1A13
   Web of Science ®Google Scholar
• KurzrockRShermanSHongDSA phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)Paper presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 21–24, 2008Geneva, Switzerland.
   Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myelogenous leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• VerweijJvan OosteromABlayJYImatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for this molecular target. Results from the EORTC Soft Tissue and Bone Sarcoma Group phase II studyEur J Cancer200339142006201112957454
   PubMed Web of Science ®Google Scholar
• SawyersCLImatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptorJ Clin Oncol200220173568356912202652
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on growth of Bcr-Abl positive cellsNat Med1996255615668616716
   PubMed Web of Science ®Google Scholar
• de GrootJWBZonnenbergBAQuarles van Ufford-MannessePA phase II trial of imatinib therapy for metastatic medullary thyroid carcinomaJ Clin Endocrinol Metab20079293466346917579194
   PubMed Web of Science ®Google Scholar
• Frank-RaueKFabelMDelormeSHaberkornURaueFEfficacy of imatinib mesylate in advanced medullary thyroid carcinomaEur J Endocrinol2007157221522017656601
   PubMed Web of Science ®Google Scholar